Singapore markets closed

Lonza Group AG (LZAGY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
60.10+0.67 (+1.13%)
As of 12:27PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close59.43
Open60.10
Bid0.00 x 0
Ask0.00 x 0
Day's range59.67 - 60.12
52-week range34.19 - 66.00
Volume400,986
Avg. volume177,383
Market cap44.643B
Beta (5Y monthly)0.61
PE ratio (TTM)35.56
EPS (TTM)1.69
Earnings dateN/A
Forward dividend & yield0.39 (0.66%)
Ex-dividend date09 May 2023
1y target est66.20
  • Reuters

    UPDATE 2-Luxury stocks pressure European equities ahead of Fed verdict

    European shares were flat on Wednesday, pressured by a sell-off in luxury stocks and in the absence of big bets by investors ahead of a crucial Federal Reserve meeting later in the day. The pan-European STOXX 600 index ended largely unchanged at 505.34 points, with the personal and household goods index housing luxury stocks, down 1.3% and leading declines.

  • Reuters

    UPDATE 3-Lonza to buy large biologics site from Roche in US for $1.2 bln

    Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion. Lonza plans to spend another 500 million Swiss francs ($562.3 million) to upgrade the facility in Vacaville, which makes monoclonal antibodies from genetically modified living cells, to produce a new generation of drugs, the company said in a statement. Roche unveiled plans to sell the site in May last year, saying it no longer needs the very large antibody volumes the plant provides, as it plans to focus on drugs targeting smaller patient populations and a range of biotechnology methods beyond monoclonal antibodies.

  • Reuters

    Lonza to buy large biologics site from Roche in US for $1.2 billion

    (Reuters) -Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion. Lonza plans to spend another 500 million Swiss francs ($562.3 million) to upgrade the facility in Vacaville, which makes monoclonal antibodies from genetically modified living cells, to produce a new generation of drugs, the company said in a statement. Roche unveiled plans to sell the site in May last year, saying it no longer needs the very large antibody volumes the plant provides, as it plans to focus on drugs targeting smaller patient populations and a range of biotechnology methods beyond monoclonal antibodies.